Where can I find news about DWTX?

The latest headlines, third-party analysis, and SEC filings for Dogwood Therapeutics, Inc. (DWTX) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are DWTX's SEC filings?

Dogwood Therapeutics, Inc. (DWTX)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are DWTX's earnings call transcripts?

Full earnings call transcripts for Dogwood Therapeutics, Inc. (DWTX) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

DWTX

Dogwood Therapeutics, Inc.

NASDAQ·Biotechnology · Healthcare

$2.66$0.02−0.75%

After hours·$2.62−1.50%

Market cap$89.45M·Market closed·Aug 26 8:00 PM UTC

News & Analysis

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic pain (“CINP”). To register, click here.
globenewswire.comAug 17, 2026 · 8:30 AM
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –
globenewswire.comAug 13, 2026 · 8:30 AM
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3% – What’s Next?
Dogwood Therapeutics, Inc (NASDAQ: DWTX - Get Free Report) shares traded up 4.3% during trading on Monday. The stock traded as high as $1.74 and last traded at $1.71. Approximately 83,119 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 68,704 shares. The stock had previously closed at
defenseworld.netAug 4, 2026 · 2:03 AM
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.
globenewswire.comJul 20, 2026 · 8:30 AM
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026
globenewswire.comJun 30, 2026 · 8:45 AM
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.comJun 16, 2026 · 12:02 PM
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
globenewswire.comMay 18, 2026 · 8:45 AM
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
globenewswire.comMay 14, 2026 · 8:30 AM

SEC Filings

10-Q
Nov 7, 2025View on SEC
8-K
Nov 6, 2025View on SEC
DEF 14A
Oct 20, 2025View on SEC
S-3/A
Oct 16, 2025View on SEC
DEFA14A
Oct 9, 2025View on SEC
8-K
Oct 9, 2025View on SEC

Frequently Asked Questions About DWTX

Where can I find news about DWTX?: The latest headlines, third-party analysis, and SEC filings for Dogwood Therapeutics, Inc. (DWTX) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are DWTX's SEC filings?: Dogwood Therapeutics, Inc. (DWTX)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are DWTX's earnings call transcripts?: Full earnings call transcripts for Dogwood Therapeutics, Inc. (DWTX) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Dogwood Therapeutics, Inc.

Frequently Asked Questions About DWTX

Dogwood Therapeutics, Inc.

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3% – What’s Next?

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board